The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Cipla has received 8 inspectional observations in Form 483
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
